Investigation of the Efficacy of Algan Hemostatic Agent in Liver Laceration Model in Rats

Mıdı, Ahmet; Kumandaş, Ali; Ekici, Hüsamettin; Bayraktar, Feyzanur; Kübra, Karapirli; Karahan, Siyami; Türk, Mustafa; Ozyurek, Hatice Emel

doi:10.14744/ejmo.2018.0008

Cited by 4 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to previous studies, it is a well-known fact that both AHA forms are effective to reduce blood loss and stop bleeding in a shorter time than control groups. [16] Studies in the literature have shown that the time of bleeding varies depending on the control group in the study, the experience of the practitioner, technical differences and laboratory conditions. Akarsu et al compared the effectiveness of Ankaferd Blood Stopper (ABS) and fibrin adhesive and the results showed that bleeding control was achieved in 18 and 17 seconds respectively.…”

Section: Discussionmentioning

confidence: 99%

Histopathological Effects of Algan Hemostatic Agent (AHA) in Liver Injury Model in Rats

Şener¹

2021

Hepatology Forum

View full text Add to dashboard Cite

Background and Aim:In this study, we aimed to assess hemostatic and histopathological impacts of Algan hemostatic agent (AHA) with liver injury model. 2Materials and Methods: 10-12 week old 24 male rats were randomly divided into three equal groups(n=8) as control(physiological saline solution), AHA liquid and AHA powder. Total of three iatrogenic cut injury were performed on anterior surface of left liver lobe. After bleeding had started, sponges soaked with physiological saline, AHA liquid, AHA powder were pressed slightly on injured area for 20 seconds in corresponding groups, respectively. Bleeding duration was measured by timer. Bleeding unended after three consecutive applications was considered as failure. Animals were sacrificed on tenth minute of the procedure. Left liver lobes were removed for histopathological examination.Results: Bleeding control success rates of AHA liquid was significantly higher than AHA powder group and both forms were effective than physiological saline. Superficial thick granulation tissue with entrapped powder residue materials was detected in AHA powder group. Liver parenchyma was intact in liquid and powder groups. Conclusion:AHA is fast-acting and applicable hemostatic agent in liver bleeding model. However, further comparative studies in various organs are required.

show abstract

Section: Discussionmentioning

confidence: 99%

Histopathological Effects of Algan Hemostatic Agent (AHA) in Liver Injury Model in Rats

Şener¹

2021

Hepatology Forum

View full text Add to dashboard Cite

show abstract

“…AHA is a new local hemostatic agent and a herbal biopolymer. Its effectiveness on experimental bleeding models is being investigated (8)(9)(10)(11). However, its effects on wound healing have not been investigated.…”

Section: Discussionmentioning

confidence: 99%

“…AHA is an effective product in preclinical studies (8)(9)(10)(11). Furthermore, the ability to produce AHA in powder and liquid forms is important in terms of ease of use in clinical practice.…”

Section: Discussionmentioning

confidence: 99%

“…Preclinical studies of AHA have been completed and clinical studies are continuing. It has been shown to be effective in some bleeding models like experimental partial splenoctomy (8), renal venous bleeding (9), liver laceration (10) and hepatectomy bleeding (11). According to the hemodynamic test, AHA primarily provides hemostasis by forming a mechanical barrier in the area where it is applied (9).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of algan hemostatic agent (AHA) on wound healing

Aksoy

Şener

Akakın

et al. 2020

Clinical and Experimental Health Sciences

View full text Add to dashboard Cite

Objective: The Algan Hemostatic Agent (AHA) is a novel herbal originated blood stopper. The aim of this study is to investigate the effect of AHA on wound healing on excisional wound model in rats. Methods: In this study, 54 adult Wistar albino rats were used. Rats were divided into 3 groups (saline, Madecassol® and AHA). Each group was then divided into 3 subgroups as the 3 rd , 7 th and 14 th days. Two wounds were created in the dorsal thoracic region of the rats. One of the lesions was used for histopathological examinations and the other for hydroxyproline measurement. In order to evaluate the wound healing, wound area were measured during the whole treatment period and animals were sacrificed at the end of the 3 rd , 7 th and 14 th days and tissue samples were taken for the determination of hydroxyproline levels. Results: AHA treatment did not cause significant difference in hydroxyproline level on days 3, 7, 14. The contraction percentage of wound area was higher in the AHA group on day 7 than that of the control group. However, the difference was not statistically significant (p>0.05). On days 3 and 14, no significant difference was detected in the contraction percentage of wound area between the control and the AHA groups. AHA and Madecassol® results of epidermis regeneration on the 14 th day, neutrophil infiltration on the 7 th day and edema on the 3 rd , 7 th and 14 th days were different in terms of histopathological parameters compared to the control group. Conclusion: Despite good histological findings, AHA did not significantly accelerate wound healing, but did not adversely affect wound healing as well.

show abstract

“…Recently, the hemostatic effects of AHA foam have been reported [10][11][12]. In addition, the effectiveness and safety of the different forms of AHA have been studied [13][14][15][16]. AHA foam generates a polymer network throughout its application area, creating a passive barrier that stops blood from leaking.…”

Section: Introductionmentioning

confidence: 99%

Effects of Algan hemostatic agent foam in rat femoral artery injury model: A randomized animal trial

et al. 2022

View full text Add to dashboard Cite

Background/Aim: Nowadays, many deaths are related to vessel injury-induced blood loss. Failure to control bleeding also increases the risk of death. This study aimed to investigate the hemostatic effects of the Algan Hemostatic Agent (AHA) foam application in a rat model in which severe femoral artery bleeding was induced. Methods: Fourteen rats were randomly assigned to two groups: (1) control (physiological saline) (n = 7) and (2) AHA foam (n = 7). The left femoral artery of the rats was incised and when the bleeding started, and the area was pressed with another sponge for 10 s in all rats. Afterwards, physiological saline solution impregnated gauze or AHA foam was placed over same area. A chronometer was started and area was checked after 2 min. If no bleeding occurred during the first 2 min of application, it was recorded as “successful”. If bleeding occurred, the same procedure was repeated up to three times. If hemostasis could not be achieved even after the third application, it was considered a failure, and “failed” was recorded. All animals were sacrificed under high anesthesia for least 10 min after the experiment. Results: Application of AHA resulted in complete (100%) control of bleeding in all rats within the first 2 min. In control group, hemostasis was achieved in 1 out of 7 (14.3%) rats by the third application. Failure was recorded for the remaining six rats. The hemostatic success rate of the AHA foam was significantly higher than the rates of control group (P = 0.005). Conclusion: AHA foam is a very effective hemostatic agent and can be applied easily on vascular trauma models. Further studies are needed to elucidate hemostatic features of AHA.

show abstract

Investigation of the Efficacy of Algan Hemostatic Agent in Liver Laceration Model in Rats

Cited by 4 publications

References 17 publications

Histopathological Effects of Algan Hemostatic Agent (AHA) in Liver Injury Model in Rats

Histopathological Effects of Algan Hemostatic Agent (AHA) in Liver Injury Model in Rats

The Effect of algan hemostatic agent (AHA) on wound healing

Effects of Algan hemostatic agent foam in rat femoral artery injury model: A randomized animal trial

Contact Info

Product

Resources

About